Introducing REXULTI® (brexpiprazole): a new PBS-listed antipsychotic for schizophrenia

October 1^st sees the PBS listing of REXULTI, a novel antipsychotic indicated for the treatment of adults with schizophrenia.

Introducing REXULTI® (brexpiprazole): a new PBS-listed antipsychotic for schizophrenia

Buy Rexulti Online at Lower Price From

Dichlorophenyl piperazines, including a recently-approved atypical antipsychotic, are potent inhibitors of DHCR7, the last enzyme in cholesterol biosynthesis. - Abstract - Europe PMC

Rexulti (Brexpiprazole) - PSYCH-MENTAL HEALTH HUB

Rexulti 1 Mg, Antipsychotic - 28 Tablets

For Alzheimer's Agitation, Promising News from Rexulti (Brexpiprazole)

Brexpiprazole Updated - Gateway Psychiatric

Dichlorophenyl piperazines, including a recently-approved atypical antipsychotic, are potent inhibitors of DHCR7, the last enzyme in cholesterol biosynthesis. - Abstract - Europe PMC

Rexulti: Package Insert

Discovery research and development history of the dopamine D2 receptor partial agonists, aripiprazole and brexpiprazole - Kikuchi - 2021 - Neuropsychopharmacology Reports - Wiley Online Library

Rexulti Approved by FDA for Major Depressive Disorder and Schizophrenia

Dichlorophenyl piperazines, including a recently-approved atypical antipsychotic, are potent inhibitors of DHCR7, the last enzyme in cholesterol biosynthesis. - Abstract - Europe PMC

Otsuka and Lundbeck Announce U.S. Food and Drug Administration (FDA) Approval of Supplemental New Drug Application (sNDA) for REXULTI® ( brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer's Disease